As many of you may know, my husband/consulting partner and I were approached by Roche Diabetes’ Accu-Chek team a few years back with a challenging project request: how could we help them best “embrace” the burgeoning online diabetes patient community (what is now known lovingly as the DOC)? Our suggestion was hosting an in-person summit, to offer us cyber-advocates a rare chance to meet each other, as well as an unprecedented “peek behind the curtain”…Read more »
Charles a.k.a. “Chip” Zimliki is a biologist who works at FDA. He’s an important person for all PWDs to know about in that he has a key role in developing the technology that will one day become a functioning Artificial Pancreas. Chip came to FDA as a grad student on fellowship doing pancreatic beta cell research for diabetes, which was always “near and dear to my heart,” he says, as a long-time type 1 diabetic…Read more »
Yesterday marks “a milestone” in the development of new technology to help automate the care and treatment of type 1 diabetes, according to JDRF!
The U.S. Food and Drug Administration unveiled its eagerly awaited Draft Guidance document for research and development of the Artificial Pancreas system, and initial reaction from JDRF — in a press conference held yesterday afternoon — was a mix of jubilation and a more measured response that they remain “guardedly optimistic” about the details…
This past weekend, 17 of the leading researchers in the diabetes community traveled to San Diego, CA, to speak at TEDxDelMar, an exciting day-long conference focused on the latest breakthroughs and continuing challenges in the search for a cure. Although the cure was the main focus of the day, TEDxDelMar also featured discussions on living well with diabetes (with talks including Dr. Steve Edelman and Dr. Bill Polonsky) and the future of diabetes technology (with…Read more »
It’s no surprise to our readers that one of the biggest issues with current diabetes management is the lag time of our current fast-acting insulins.
Although light years ahead of what patients had in the past, current fast-acting insulins still aren’t quite up to snuff to handle post-prandial spikes. This is becomes a barrier for developing an Artificial Pancreas, as the insulin can’t respond quickly enough to sensor data in a closed-loop system.